Skip to main content
Caplight Logo









FimmCyte

FimmCyte

Private
BaselHealthcare & Life Scienceshttps://fimmcyte.com/

Last Round

Convertible Debt

Feb 29, 2024

Total Funding Raised

$2.69M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

FimmCyte is a biotechnology company developing targeted immunotherapies for chronic fibro-inflammatory diseases with an initial focus on endometriosis.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

endometriosis treatmentdisease-modifying therapytargeted immunotherapyfirst-in-class drugnon-hormonal therapyantibody platformfibro-inflammatory diseasepreclinical biotechpharma licensingwomen's healthantibody therapyuniversity spin-off

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

FimmCyte Comparables

Compare FimmCyte with similar companies based on industry and business-model similarity.

FimmCyte comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Oriva Therapeutics
86%
EndoCyclic Therapeutics
84%
Sur180 Therapeutics
83%

FimmCyte Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtFeb 29, 2024
Convertible DebtSep 5, 2023
GrantJul 13, 2022

Key People

Founding team and executive leadership

Mohaned Shilaih

CEO

Executive Team

FimmCyte Investors

Notable investors and investment history

FimmCyte investors
InvestorRounds
Venture KickGrant
BioInnovation InstituteConvertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 13, 2026

    Open roles increased from 0 to 2, representing 29% of headcount.

  • Mar 25, 2025

    Monthly visitors grew 254% MoM, reaching 1.4K.

FimmCyte Filings

Explore SEC and related filing metadata, where available.

FimmCyte filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about FimmCyte's valuation, stock price, and market status.

Is FimmCyte a public or private company?

FimmCyte is a private company.

What is the current stock price of FimmCyte?

FimmCyte is a private company with no public stock price. No recent secondary market data is available.

How much is FimmCyte worth (valuation)?

Valuation information for FimmCyte is not publicly available.

Can I buy FimmCyte stock?

FimmCyte shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was FimmCyte's last funding round?

Funding round information for FimmCyte is not publicly available.

Who are the main investors in FimmCyte?

Investor information for FimmCyte is not publicly disclosed.

Will FimmCyte IPO soon?

No public IPO plans have been announced for FimmCyte.

How can I track FimmCyte secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor FimmCyte's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBasel
Employee Range6
Year Founded2022
Last FundingFeb 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?